SwitzerlandSwitzerland

Molecular Partners signs US$420 million contract on antibody mimetic with Allergan

05.05.2011

Zurich/Schlieren – Swiss Molecular Partners AG has bagged a US$45 million upfront payment and the option for additional US$345 million milestones from Allergan Inc for an exclusive licence of its Phase 2 anti-VEGF antibody mimetic MP0112 for the treatment of retinal diseases. In addition, Molecular Partners could receive tiered double-digit royalties on any future sales of MP0112. Allergan gains exclusive global rights for MP0112 for ophthalmic indications of the so-called DARPin molecule. DARPins are temperature stable, 14KDa scaffolds of 2-4 domains of the ankyrin protein motif that mimic the antigen binding capacities of antibody drugs while offering advantages of smaller molecules. Data on MP0112 from two separate phase I/IIa trials in wet age-related macular degeneration (wetAMD) and diabetic macular edema (DME) suggest that MP0112 is well-tolerated and has a potentially long lasting effect on vision gain after one single injection. In the studies, for most patients in the cohorts treated with the higher dose of the investigational compound, the potential beneficial effect on visual acuity lasted for approximately 16 weeks.

SwitzerlandSwitzerland

22.08.2011

Liestal – Swiss Santhera Pharmaceuticals and researchers from Newcastle University have published the results from a pivotal clinical trial demonstrating that the firm’s synthetic coenzyme Q10 derivative idebenone significantly...

SwitzerlandSwitzerland

18.08.2011

Basel – Swiss pharma and diagnostics major Roche AG has agreed to buy privately-held Heidelberg-based mtm laboratories AG, a specialist for kits detecting pre-stages of cervical cancer, for up to EUR190m. Under the terms of the...

SwitzerlandSwitzerland

16.08.2011

Reinach – Evolva SA has got its hands on up to €30m of fresh capital. The Swiss specialist for synthetic biology announced that it has entered into a Standby Equity Distribution Agreement (SEDA) with YA Global Master SPV Ltd. (YA...

SwitzerlandSwitzerland

15.08.2011

Basel/Waltham - Expecting to be bought by Novartis, U.S. biopharmaceutical firm Proteon Therapeutics Inc. has delivered a new $15.2 million financing. The Swiss pharmaceutical company Novartis obtained exclusive option to acquire...

SwitzerlandSwitzerland

03.08.2011

Zurich - Most of the European men share the DNA of the well known Egyptian pharaoh, Tutankhamun, also called the boy King Tut. According to geneticists at Zurich-based genealogy firm iGENEA, up to 70 percent of British men and...

SwitzerlandSwitzerland

13.07.2011

A big financier of biotech deals could be back on track soon. Novartis is interested in further acquisitions, CEO Joe Jimenez said in an interview published by the "Aargauer Zeitung", a Switzerland- based newspaper.The drugmaker...

SwitzerlandSwitzerland

11.06.2011

Basel – Swiss crop group Syngenta plans to construct a new biotech research facility adjacent to its existing research campus at the Research Triangle Park in North Carolina (US). The US$71m investment is scheduled to begin in...

Displaying results 31 to 40 out of 276

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/3/article/molecular-partners-signs-us420-million-contract-on-antibody-mimetic-with-allergan.html

Events

All Events

Stock list

All quotes

TOP

  • THROMBOGENICS (B)9.69 EUR9.24%
  • NOVACYT (F)4.80 EUR9.09%
  • HYBRIGENICS (F)1.85 EUR7.56%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THERAMETRICS (CH)0.08 CHF-11.11%

TOP

  • WILEX (D)3.15 EUR331.5%
  • SANTHERA (CH)68.90 CHF100.3%
  • ADDEX (CH)4.06 CHF84.5%

FLOP

  • MERCK KGAA (D)64.28 EUR-49.5%
  • HYBRIGENICS (F)1.85 EUR-28.3%
  • PROSENSA (NL)9.24 USD-28.0%

TOP

  • SANTHERA (CH)68.90 CHF3507.3%
  • GW PHARMACEUTICALS (UK)422.75 GBP771.6%
  • PAION (D)2.80 EUR305.8%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.0%
  • PROSENSA (NL)9.24 USD-69.0%

No liability assumed, Date: 24.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products